Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-18T16:38:27.317Z Has data issue: false hasContentIssue false
  • English
  • Français

The Tissue Plasminogen Activator/Plasmin System May Act Through Cleavage of Pro-BDNF to Increase Risk of Substance Abuse

Published online by Cambridge University Press:  07 November 2014

Cheng-Dien Hsu  and
Shih-Jen Tsai
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter
Information
CNS Spectrums , Volume 15 , Issue 6 , June 2010 , pp. 350
Copyright
Copyright © Cambridge University Press 2010

References

1. Spanagel, R, Weiss, F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999; 22(11): 521–527.Google Scholar
2. Nagai, T, Yamada, K, Yoshimura, M, et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci U S A. 2004; 101(10): 3650–3655.Google Scholar
3. Nagai, T, Noda, Y, Ishikawa, K, et al. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem. 2005; 92(3): 660–667.Google Scholar
4. Nagai, T, Ito, M, Nakamichi, N, et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci. 2006; 26(47): 12374–12383.Google Scholar
5. Pawlak, R, Melchor, JP, Matys, T, Skrzypiec, AE, Strickland, S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A. 2005; 102(50): 443–448.Google Scholar
6. Hyman, C, Hofer, M, Barde, YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350 (6315): 230–232.Google Scholar
7. Horger, BA, Iyasere, CA, Berhow, MT, Messer, CJ, Nestler, EJ, Taylor, JR. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosi. 1999; 19(10): 4110–4122.Google Scholar
8. Grimm, JW, Lu, L, Hayashi, T, Hope, BT, Su, TP, Shaham, Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci. 2003; 23(3): 742–747.Google Scholar
9. Lu, L, Dempsey, J, Liu, SY, Bossert, JM, Shaham, Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J Neurosci. 2004; 24(7): 1604–1611.Google Scholar
10. Cheng, CY, Hong, CJ, Yu, YW, Chen, TJ, Wu, HC, Tsai, SJ. Brainderived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res. 2005; 140(1–2): 86–90.Google Scholar
11. Pang, PT, Teng, HK, Zaitsev, E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004; 306 (5695): 487–491.Google Scholar
12. Lu, B, Pang, PT, Woo, NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005; 6(8): 603–614.Google Scholar